Physician profile
Fei Lu
NPI 1841372869
$11,090.14
in general payments reported to CMS, 2019-2025
40 companies · $902 in 2025
The $902 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $569 · 2021: $347 · 2022: $1,265 · 2023: $6,394 · 2024: $899 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,298 · Food and Beverage: $3,617 · Consulting Fee: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,298.22 |
| Food and Beverage | $3,617.17 |
| Consulting Fee | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,669.40 | 2019-2025 | Accent, Aveir, Gallant |
| Boston Scientific Corporation | $1,761.13 | 2021-2025 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $796.71 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $541.56 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $533.60 | 2019-2025 | |
| Medtronic, INC. | $508.04 | 2023 | |
| Merck Sharp & Dohme LLC | $461.74 | 2022-2025 | Verquvo, Keytruda |
| Amgen INC. | $395.39 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $353.50 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $237.65 | 2020-2024 | Xarelto |
| Baxter Healthcare | $232.72 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $220.15 | 2020-2024 | Eliquis, Camzyos |
| Biosense Webster, INC. | $137.08 | 2020 | |
| Alnylam Pharmaceuticals INC. | $134.47 | 2022-2025 | Onpattro |
| Cvrx, INC. | $130.89 | 2024 | Barostim Neo System |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.